Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

AATOSSA THERAPEUTICS, INC.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
A

ATOSSA THERAPEUTICS, INC.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
    Sep 24, 2026Atossa Therapeutics, Inc. | News Releases
  • Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
    Aug 7, 2026Atossa Therapeutics, Inc. | News Releases
  • Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
    Jul 28, 2026Atossa Therapeutics, Inc. | News Releases
  • Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
    Jul 21, 2026Atossa Therapeutics, Inc. | News Releases
  • Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
    Jun 12, 2026Atossa Therapeutics, Inc. | News Releases
  • Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
    Jun 11, 2026Atossa Therapeutics, Inc. | News Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$2.47Close ยท Oct 7, 2026